SEOUL, April 28 (Korea Bizwire) — SK Bioscience Co., a pharmaceutical affiliate under SK Group, said Friday it will invest 2.4 trillion won (US$1.79 billion) by 2028 as it is seeking to further expand its contract manufacturing business. The proposed investment — twice the amount the company had spent in the past five years — [...]
SEOUL, Oct. 25 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Tuesday it has signed a deal to join hands with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop messenger RNA (mRNA) vaccines. Under the agreement, SK Bioscience will receive US$140 million for the project from CEPI, an Oslo-based international public-private partnership, [...]
SEOUL, Sept. 2 (Korea Bizwire) — SKYCovione, South Korea’s first homegrown COVID-19 vaccine developed by SK Bioscience Co., has been proven to be effective against coronavirus omicron subvariants when administered as a booster shot, a state-run research center said Friday. The Center for Infectious Disease Research (CIDR) said it has confirmed through research SKYCovione’s efficacy [...]
SEOUL, June 29 (Korea Bizwire) — South Korea on Wednesday approved the use of SKYCovione, the country’s first homegrown COVID-19 vaccine developed by SK Bioscience Co., taking a major step toward achieving vaccine sovereignty in the fight against the pandemic. The Ministry of Food and Drug Safety (MFDS) said it approved the use of SKYCovione, [...]
SEOUL, June 27 (Korea Bizwire) — South Korea’s first COVID-19 vaccine candidate, developed by SK Bioscience Co., has received an approval recommendation from a government advisory group of pharmaceutical experts, officials said Monday, pushing the vaccine candidate one step closer to commercial launch. The Ministry of Food and Drug Safety said GBP510, the vaccine candidate [...]
SEOUL, May 23 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. said Monday it has secured a US$31.3 million deal from the Pan American Health Organization (PAHO) to supply chickenpox vaccines to Latin American countries. SK Bioscience said it has recently delivered its first batch of shipments of SKY Varicella, the company’s chickenpox [...]
SEOUL, March 31 (Korea Bizwire) — South Korean vaccine maker SK Bioscience Co. will expand its business portfolio to secure a new growth engine with the aim of becoming a global top-tier biotechnology firm by 2025, its chief said Thursday. Celebrating the one-year anniversary of its initial public offering (IPO) on the main bourse, the [...]
SEOUL, Dec. 24 (Korea Bizwire) — SK Bioscience Co., a vaccine unit of South Korea’s SK Group, said Friday it has extended an agreement to manufacture a component of the U.S.-based biotechnology company Novavax Inc.’s COVID-19 vaccine by one more year. Under the extended agreement, SK Bioscience will reserve additional manufacturing capacity to produce antigen, [...]
SEOUL, Dec. 18 (Korea Bizwire) — South Korean drugmakers have begun the process to develop COVID-19 vaccines that are effective against the new omicron variant amid concerns that the highly transmissible strain may become a dominant one soon. As the omicron variant fuels fears around the world that the pandemic could rage during the winter [...]
SEOUL, Oct. 6 (Korea Bizwire) — South Korean drugmaker SK Bioscience Co. said Wednesday it has signed an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to extend capacity reservations for manufacturing COVID-19 vaccines by the end of 2022. The agreement was signed between SK Bioscience CEO Ahn Jae-yong and Richard Hatchett, CEO of [...]